Fig. 2

Criteria for the selection of the frontline chemotherapy regimen (carboplatin plus etoposide versus cisplatin plus etoposide) to be administered in combination with immunotherapy (A), and reasons for early discontinuation of chemotherapy in the participating medical centers (B). *Other include: prescribing practices; a decision to administer carboplatin over cisplatin because its use is approved in combination with both atezolizumab and durvalumab; treatment tolerance